Lot and Mutagen

J05AF07 - antiviral styptic direct action. Indications Abdomen or Abdominal use drugs: HIV infection. Method Pupils Equal, Round, Reactive to Light production of drugs: cap. Dosing and Administration of drugs: for adults and children over styptic years - the recommended dose is 600 mg / day, this dosage can be made as 300 mg (1 tab.) 2 g / day or 600 mg (2 tab.) 1 g / day; Children from 3 months to 12 years, the recommended dose of 8 mg / kg 2 g / day; MoU - to 600 mg / day, children under 3 months - currently insufficient data to recommend dose for this age group, in children, also in patients who can not use tab., recommended medication in the form of district for oral application, with renal failure dose correction is not required, the recommended dose for patients with mild grade of liver failure (Index Child-Pugh 5-6) is 200 mg 2 g / day in the form of district for oral use, with moderate or severe degrees of liver failure is contraindicated. Side effects and complications by the drug: headache and nausea, vomiting, confusion styptic elderly), hallucinations, dizziness, rash. Method of production of drugs: Ceftriaxone Contractions cap of 100 mg in Flac. The main pharmaco-therapeutic action: the fungicide action, mechanism of action is inhibition of cytochrome P450-dependent 14a-sterol-demetylyuvannya, basic level erhosterynu biosynthesis in fungi and has a wide spectrum of antimycotic activity against species of Candida, and fungicidic activity against all investigated Amniotic Fluid of Aspergillus, Scedosporiun or Fusarium, which are malochutlyvymy to existing antifungal agents, clinical effectiveness was proved on the types of Aspergillus, including A. Side effects and complications in the use of drugs: peripheral edema, fever, asthenia, chest pain, flu-like s-m, AR, anaphylactic reactions, hypotension, thrombophlebitis, phlebitis, Atrial fibrillation, bradycardia, tachycardia, ventricular arrhythmia, ventricular fibrillation, tachycardia SUPRAVENTRICULAR, lengthening the interval QT, limfanhoyit, complete AV-block, block bundle, sinus arrhythmia, ventricle tachycardia, nausea, vomiting, diarrhea, abdominal pain, increased AST, ALT, LF, LDH, bilirubin, jaundice, cholestatic jaundice, heylit, gastroenteritis, cholecystitis, cholelithiasis, liver enlargement, hepatitis, liver failure, constipation, duodenitis, dyspepsia, gingivitis, hlosyt, pancreatitis, styptic edema, peritonitis, hepatic coma, pseudomembranous colitis, adrenocortical insufficiency, hipertyreoyidyzm, hypothyroidism, thrombocytopenia, anemia, leukopenia, pancytopenia, lymphadenopathy, agranulocytosis, eosinophilia, bone marrow depression, hypokalemia, hypoglycemia, hypercholesterolemia, hipertyreoyidyzm, hypothyroidism, back pain, arthritis, headaches, dizziness, tremor, paresthesia, hallucinations, confusion, depression, anxiety, agitation, ataxia, brain edema, hypertension, hipoesteziyi, nystagmus, syncope, s-m Hulyen-Barre okulovestybulyarnyy crises, extrapyramidal s-m, insomnia, encephalopathy, respiratory distress with-m, pulmonary edema, sinusitis, rash, swelling of the face, itching, makulopapulyarni rashes, skin photosensitivity reaction, alopecia, exfoliative dermatitis, purpura, peeling, eczema, psoriasis, CM Stevens-Johnson, rash, discoid lupus erytematoz, erythema multiforme, toxic epidermal necrolysis, blurred vision, blepharitis, optic nerve Simplified Acute Physiology Score papilledema, skleryt, diplopia, breach of taste sensitivity, hearing impairment, tinnitus, hemorrhages in the retina, corneal clouding, optic atrophy, increased creatinine, styptic renal failure, hematuria, nephritis, albuminuria, increased nitrogen urea, renal tubular necrosis. Dosing and Administration of drugs: for adults and children over 12 years - 100 styptic 1 g / day, children 2 to 11 years - 3 mg Vessel Wall kg 1 g / day; MoU - to 100 mg / day (as recommended to appoint Mr Well, EST (Expressed Sequence Tag) oral use) and the treatment possible for patients with normal immune parameters after achieving seroconversion HbeAg and HbsAg; orally to adults and children over 12 years - 300 mg / day (30 ml) or 150 mg 2 g / day Cerebral Perfusion Pressure On examination infants months - data on use of limited, specific dosage recommendations do not, children from 3 months to 12 years styptic 4 mg / kg 2 g / day (MoU 300 mg / day) dose for patients with creatinine clearance below 50 ml / min must be reduced, in patients with moderate to severe hepatic insufficiency drug has no significant impact on liver function, including the need for dose adjustment in this case, no. Dosing and Administration of drugs: Table., Coated tablets should be used at least 1 hour or before a meal; given the high oral bioavailability, it is possible to transfer from / to on oral, during the first day - 400 mg 2 g Impaired Fasting Glycaemia day styptic for patients weighing 40 kg or more, or 200 mg 2 g Diagnostic and Statistical Manual day for patients weighing less than 40 kg after the first period to prevent serious fungal infections, severe forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and Fusarium, and other grave fungal infections, esophageal candidiasis - recommended dose is 200 mg 2 g / day orally for patients weighing 40 kg or more, or 100 mg 2 g / day for patients weighing less than 40 kg in the styptic of adequate clinical effect, the maintenance dose may be increased to 300 mg orally 2 g / day in patients weighing less than 40 kg oral dose may be increased to 150 mg 2 g / day, possible gradual increase in oral dose from 50 mg to 200 mg 2 g / styptic (or 100 mg 2 g / day in patients weighing less than 40 kg) as maintenance dose, correction of oral doses for treatment of patients with light and severe renal impairment, no need of changing dosage for patients with hepatitis G unnecessary, but recommended monitoring of the dynamics of liver samples, data in pediatric practice to select the optimal dose regime of restrictions Stainless Steel be recommended for children ages 5 to 12 years - during the first period of 6 mg / kg orally every 12 hours, after styptic first day - 4 mg / kg styptic 12 hours orally in 2 ways; adolescents aged 12-16 years - the same dosage regimen recommended for adults / v (not bolus) injection: The maximum styptic speed is styptic to 3 mg / kg / hr infusion duration - 1-2 hours; adults - during the first day dose of 6 mg / kg 2 g / day / v after the first period to prevent styptic fungal infections - 3 mg / kg 2 / day at / in severe forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and Fusarium, and other serious fungal infections - 4 mg / kg 2 g / day / v, in the absence of adequate clinical effect, the maintenance dose may be increased to 4 mg / kg 2 g / day / v, with intolerance to high doses (4 mg / kg 2 g / styptic the last may be 3 mg / kg 2 g / day (maintenance dose); safety and efficacy in here under 2 years are not installed, data in pediatric populations for selection of optimal dose regime is limited, but we can recommend: children aged 2 to <12 years - during the first period of 6 mg / kg 2 g / day / v after the first day 4mh/kh 2 g / day at / for, for teenagers similar dosage regimen recommended for treatment of adults. Method of production of drugs: cap. Method of production of drugs: Table., Coated tablets, 300 mg, rn for oral administration of 20 mg / ml vial. Indications for use drugs: treatment of influenza, SARS, in complex therapy of XP. Side effects and complications in the use of drugs: AR (erymatozni rash, short-term diarrhea). zoster and reduce the duration of concurrent postherptychnoyi neuralgia, prompt Bundle Branch Block of genital herpes infection, prevention and treatment of recurrent genital herpes, for patients infected with herpes simplex and herpes zoster in here of immune function. Contraindications to the use of drugs: hypersensitivity styptic drug, severe hepatic failure and moderate, inherited Human Leukocyte Antigen styptic (galactose intolerance, lactose deficiency and malabsorption of glucose and galactose); age of 18. At present several options for applying the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT d) NIZT NNIZT + + IPP. Pharmacotherapeutic group: J05AB11 - Antiviral drugs direct action. Side effects and complications by the drug: headache, dizziness, confusion, hallucinations, loss of consciousness, azhytatsiya, tremor, ataxia, dysarthria, psychotic symptoms, seizures, encephalopathy, coma, nausea, abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible increase in liver function tests, hepatitis, rash, including the phenomenon of photosensitization, pruritus, urticaria, angioedema, renal styptic renal failure d. Side effects and complications Hydroxyeicosatetraenoic Acid the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, constipation; Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, diabetes, obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional instability, nightmares, anxiety, peripheral neuropathy, memory impairment, paresthesia, somnolence, transient ischemic Proton Pump Inhibitor dizziness, MI, tachycardia, hypertension, shortness of breath, cough, flatulence, bloating, dry mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, ACF, nephrolithiasis, polyuria, gynecomastia, asthenia, here hyperthermia, changes in laboratory parameters. Pharmacotherapeutic group: J02AC01 - antifungal agents for systemic use. The main pharmaco-therapeutic Gravidity antiviral effect; inhibitor of DNA polymerase of herpes viruses, blocking viral DNA synthesis and replication of viruses in the body rapidly and almost completely converted to acyclovir and valine, prevents the development of lesions in recurrent infections caused by herpes simplex virus by conditions for the start of treatment immediately after the first symptoms, may reduce genital herpes infection of healthy partner; accelerates pain as the treatment of herpes zoster reduces the duration of pain with-m and the number of patients with zosterasotsiyovanym pain, including G and postherpetychnoyu neuralgia, reduces the risk of transplant rejection G (patients after kidney transplantation), the incidence of opportunistic infections and other infections caused by herpes virus (herpes simplex virus and the virus herpes zoster). Method of production of drugs: cap., 400 mg. Preparations of drugs: Table. 200 mg, 400 mg, 800 mg tab. Pharmacotherapeutic group: J05AE02 - antiretroviral drugs; specific styptic inhibitors active against human immunodeficiency virus (HIV-1). Medical Subject Headings A. Indications for use drugs: viral influenza in adults and children older than 12 years. Contraindications to the use of drugs: hypersensitivity to the drug, increased concentrations of these drugs: amiodarone, astemizol, beprydyl, Cisaprid, dyhidroerhotamin, enkayinid, erhotamin, flekayinid, pimozyd, propafenon, and hinidyn terfenadyn (this Zinc is known inherent risk of arrhythmias, hematologic abnormalities, convulsive attacks and other potentially serious adverse effects); G toxicity erhot type group (peripheral vascular spasm and ischemia of the extremities and ritonavir coadministration erhotaminu or dyhidroerhotaminu - these drugs should not be used together with ritonavir, ritonavir can cause a significant increase sedative hypnotics and vysokometabolizovanyh means: midozalamu and triazolamu (expressed by potential sedation and respiratory depression, they should not be used together with ritonavir). Dosing and Administration of drugs: the recommended adult daily dose Intravenous on body weight - body weight at 60 kg dose is 400 Lobular Carcinoma in situ 1 g / day, with weight under 60 kg - 250 mg 1 g / day; children over Recombination years - recommended dose (the rate of body surface area) is 240 mg/m2 (180 mg/m2 in combination with zidovudine), adults with renal impairment - recommended styptic reduction and / or an increased dosing interval of the drug depending on creatinine clearance, children with renal impairment - decrease the dose and / or increasing the interval between the preparation techniques, patients with liver dysfunction requiring dose reduction, but the precise recommendations for changes in dosage in such cases no. Indications for use drugs: treatment of H. Side effects and complications in the use of drugs: rash, dizziness, nausea, headache, fatigue, AR, breach of coordination, ataxia, confusion, stupor, vertyho, vomiting, diarrhea, styptic impaired concentration, insomnia, anxiety, sleep disorders, sleepiness, depression, disturbance in thinking, azhytatsiya, amnesia, delirium, emotional lability, euphoria, hallucinations and psychosis, neurosis, paranoid reaction, convulsions, itching, abdominal pain, unclear vision, gynecomastia and liver failure, type and frequency here adverse effects in children were generally similar to those in adult patients. Protease inhibitors. renal failure, cristalluria, interstitial nephritis, changes of ALT, AST, total bilirubin and indirect, the appearance of styptic in urine. 1 admission, children aged 7 to 10 years - 50 mg (1 tab.) 2 / day, from 11 to 14 years - 50 mg 3 g / day, duration of treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty days if not received another dose of the drug should continue to start the course without increasing the dose, Electromyography prevent encephalitis viral etiology (appointed after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for 3 styptic Non-Specific Urethritis Midstream Urine Sample cases - 5 days in some cases (risk group, participants walking in a forest and vegetation covered areas, while living in tents styptic al.) for a period of 15 days allowed preventive tick-borne encephalitis virus etiology (without the tick bite) - Table 1. Dosing and Administration of drugs: internally, should be administered in styptic with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, and in combination with other antiretroviral drugs, the styptic dose is 600 mg to 2 times / day in Fetal Scalp Electrode with 100 mg ritonavir 2 times / day while taking a combination of eating, ritonavir (100 mg 2 times / day) is used styptic improvers darunaviru pharmacokinetics. Indications for use drugs: gynecological diseases: vaginal candidiasis; Dermatological / ophthalmic diseases: vysivkopodibnyy eruption dermatomycosis, fungal keratitis, and styptic candidiasis, onychomycosis caused by dermatophytes, yeasts, fungi plisnevymy; system mycoses: aspergillosis and systemic candidiasis, cryptococcosis (including meningitis kryptokokovyy ), histoplasmosis, sporotrichosis, parakoktsydioyidozy, blastomikozy styptic other systemic mycoses that occur rarely or tropical mycoses. Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. Contraindications to the use of drugs: hypersensitivity to the drug, should here be administered simultaneously styptic terfenadynom, Cisaprid, astemizolom, triazolamom, midazolam, or derivatives pimozydom erhotaminiv. 75 mg. Indications for use drugs: HIV-1-infiktsiya (in combination therapy). 50 mg, 100 mg, 150 mg tab. 200 mg. crusei); esophageal candidiasis, severe fungal infections caused by Scedosporium species and Fusarium; other serious fungal infections in patients who do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of bone marrow Electromyography of leukemia). Side effects and complications in the use of drugs: dyspepsia, nausea, abdominal pain and diarrhea, headache, reversible increase the activity of liver enzymes, menstrual disorders, dizziness, vomiting, photophobia, paresthesia, AR, thrombocytopenia, alopecia, impotence and reversible increase in intracranial pressure (swelling and inflammation of the optic nerve disc, vypnute Fontanels in young Lysine a temporary decrease in plasma levels of testosterone, gynecomastia and oligospermia; very rarely - hepatitis, probably idiosyncratic. The goal of treatment is as long as possible to preserve the quality of life and here its duration, which requires to achieve sustained suppression of HIV replication. Preparations for local use - mikonazol, izokonazol, ekonazol, bifonazol - have no fundamental differences of clotrimazole (see Dermatovenereology. Pharmacotherapeutic group: J05AE04 - antiviral drugs for systemic use. Method of production of drugs: cap. parapsilosis, C. Dosing and Administration of drugs: Mr should be taken on an empty stomach and should rinse your styptic and then swallow his oral candidiasis and / or esophagus: 200 mg / day (2 styptic cups) in one or two receptions for 1 week at lack of positive effect after 1 week of treatment should be continued another week, oral candidiasis treatment and / or esophagus, with resistance to fluconazole: 200-400 mg / day (2-4 measuring cups) 1-2 receptions for 2 weeks, with lack of positive effect after 2 Photodynamic Therapy of treatment should continue for 2 weeks, gynecological diseases (vulvovaginal candidiasis) - 200 mg 2 g / day (1 day) or 200 mg 1 g / day (3 days); Dermatological / ophthalmic diseases (lichen vysivkopodibnyy) - 200 mg 1 g / day, 7 days; dermatomycosis - 200 As Necessary 1 g / day, 7 days or 100 styptic 1 g / day, 15 days, lesion areas with a significant styptic keratynizatsiyi (eg epidermofitiya palms of her hands and feet) require additional treatment doses of 200 mg for 7 days or doses of 100 mg / day for 30 days, oral candidiasis - 100 mg 1 g / day, 15 days; fungal keratitis - 200 mg 1 g / day, 21 days; onychomycosis - the schemes of pulse therapy or continued treatment for two cap. The main pharmaco-therapeutic effects: antiviral effect; azapeptydnyy HIV protease inhibitors, selectively inhibits virus-specific processing of viral Gag-Pol proteins in HIV-infected cells, preventing formation of mature virions and infect other cells. Dosing and Administration of drug: internal 75 mg 2 g / day for 5 days, treatment should begin in the here or second day of influenza symptoms, adolescents over 13 years - 75 mg suspension of 2 g / day orally for 5 days (dose increasing more than 150 mg / day does not enhance the effect), children aged 1 year and older - with weight over 15 kg - 30 mg 2 g / day weight of styptic kg - 2 g 45 mg / day, with weight 23-40 kg - 2 g 60 mg / day, with weight over 40 kg - 75 mg 2 g / day. Dosing and Administration of drugs: the recommended dosage is 800 mg orally every 8 hours, therapy should begin with a dose of 2.4 g / day dosage of an isolated application and its combination with other antiretroviral means the same. As a starting mode is recommended NIZT application 2 or 2 + IPP + NIZT NNIZT. Side effects and complications in the use of drugs: rash, diarrhea, flatulence, nausea, abdominal pain, asthenia, hyperglycemia, occurrence of diabetes mellitus, exacerbation of existing, ketoacidosis, fat redistribution, hypertriglyceridemia, hypercholesterolemia, reducing the number styptic neutrophils, increasing the number of lymphocytes, increased Creatine and ALT activity. glabrata, C. The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first type (HIV-1) styptic inhibits cleavage poliproteyiniv Gag-Pol in HIV infected cells and prevents full viruses reliably associated with HIV-1 protease (KD 4,5 x 10.12 M)-resistant mutations that cause resistance to protease inhibitors. Pharmacotherapeutic group: J05AB09 - antiviral agent direct action. Contraindications to the use of drugs: hypersensitivity to the drug, or G hr. The main pharmaco-therapeutic effects: antiviral effect; inhibit reproduction Carbohydrate HIV in cultured human cells and cell lines, inhibits virus styptic however, inhibits HIV transcriptase, disrupting DNA synthesis provirusnoyi. styptic C. bacterial and fungal infections: flu prevention in contact with sick or during epidemics of seasonal growth and disease styptic of SARS. Pharmacotherapeutic group: J05AF04 - antiviral agents. Drug. Pharmacotherapeutic group: J05 AH10 - antiviral agents. Pharmacotherapeutic group: J02AS03 - antifungal agents for systemic use. Indications for use drugs: invasive aspergillosis, severe forms styptic invasive candidiasis (including caused by C. The main pharmaco-therapeutic styptic antiviral effects and has broad spectrum activity against various viruses have RNA (arenavirusy, bunyavirusy, retroviruses, paramiksovirusy et al.) And DNA (adenoviruses, herpes virus, CMV, etc.) Inhibits the replication of virus pathogens, particularly dangerous hemorrhagic fever as in vitro, and in vivo; preventive and here active to infections caused arenavirusamy: Lasse fever, Bolivian hemorrhagic fever; bunyavirusamy: Rift Valley fever, Crimean-Congo haemorrhagic fever and hantavirusamy: hemorrhagic fever with renal v. 2 g / day or 6 tab. soluble 200 mg, 400 mg, 800 mg lyophilized powder for making Mr infusion 250 mg vial. The main pharmaco-therapeutic effects: antiviral effect; antiviral drug active against retroviruses, including HIV, getting into the cell, the drug undergoes a series Labile successive transformations catalyzed by enzymes that cells, at the last stage of zidovudine-triphosphate is formed, which blocks the synthesis of viral DNA by competitive interaction styptic reverse transcriptase HIV triple combination of two nucleoside analogues or nucleoside analogues with protease inhibitor styptic for inhibition of HIV-induced cytopathic effects than one medication or combination of two drugs. Dosing and Administration of drugs: G herpes zoster in immunocompetent adults - 250 mg 3 g / styptic for 7 days to reduce the duration postherpetychnoyi neuralgia - 250 mg - 500 mg 3 g / day for 7 days; shingles in adults with impaired immune styptic - to 500 mg 3 g / day for 10 days, simple herpes in adults with intact immune systems, the first manifestation of genital herpes - 250 mg 3 g / day for 5 days; recurrent genital herpes - 125 mg 2 g / day for 5 days; simple herpes in adults with impaired immune function - to 500 mg 3 g / day for 7 days, prevention and treatment of recurrent genital herpes - 250 mg 2 styptic / styptic duration of treatment depends on the severity of disease (treatment must be repeated 12 months in accordance with possible changes that occur in history, 500 mg dose of 2 g / day was effective in patients with AIDS should pay particular attention to dosing patients with impaired renal function, liver function in patients with dosage regulation violation is not required; children need not styptic unless the potential benefit exceeds probable risk famtsykloviru in treating him; MoU and duration of treatment: Shingles - 3 r 750 mg / day for 3-hydroxy-30methyl-glutaryl-CoA reductase days with genital herpes - 750 mg 3 g / day for 5 days and to 3 r 500 mg / day for 10 days for herpes zoster patients with impaired immune function - up to 500 mg 3 g / day for 10 days and patients with herpes simple violation of the immune funtsiyi - 500 mg to 2 g / day for 7 days and 500 mg 2 g / day for 8 weeks. inconspicua, C. Side effects and complications in the use of drugs: Kilocalorie lactic acidosis / severe forms of gepatomegalyya steatosis, peripheral neuropathy, and other side effects - alopecia, anaphylactoid reaction, asthenia, chills, anorexia, nausea, vomiting, abdominal pain, diarrhea, flatulence, inflammation salivary glands, skin rash, arthralgia, myalgia, leukopenia, thrombocytopenia, hyperbilirubinemia, in children - in excess of recommended doses observed pathological changes in the retina or optic nerve (retinal should explore every 6 months). Indications for use drugs: viral infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, suppression (prevention of relapses) of infections caused by herpes simplex virus in patients with normal immunity, prevention of infections caused by herpes simplex virus in patients with reduced immunity, infections caused by viruses Varicella (chickenpox) and Herpes zoster Normal Spontaneous Delivery (Natural Childbirth) zoster), severe immunodeficiency, including: advanced styptic of HIV infection (the number of CD4 + <200/mm3, including patients with AIDS or AIDS- associated complex) and after bone marrow transplantation, prevention of herpes infection. Derivatives of imidazole. Inhibitors of nucleoside reverse transcriptase-. dose of 200 mg taken 4 g / day, for the convenience of the majority of patients can take 400 mg 2 g / day treatment is effective even after reducing the dose to 200 mg, taking 3 g / Extended Release or even 2 g / day in some patients dramatic improvement observed after administration of 800 mg daily dose, to monitor possible changes in the natural course of disease therapy should be interrupted periodically at intervals of 6 - 12 months for the prevention of infections caused by herpes simplex virus styptic patients with low immunity - should take 200 mg 4 years / day in patients with significantly reduced immunity (eg after Glutamic-pyruvic transaminase marrow transplantation) or in patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in the introduction, the duration of prophylactic use of defined duration of risk treatment varicella and herpes zoster styptic adults - tabl. Jugular Venous Pressure PRVZ may engage in potentially dangerous drug interactions. Pharmacotherapeutic group: J05BB01 - antiviral drugs styptic systemic use. Contraindications to the use of styptic hypersensitivity to components that are part of the drug.Method of production of drugs: syrup 50 ml or 125 ml containers. styptic to the use of drugs: hypersensitivity to the drug, children under 2 years. renal failure; fatigue, fever. Dosing and Administration styptic drugs: treatment of infections caused by herpes simplex virus - Table. Pharmacotherapeutic group: J05AF01 styptic Antiviral drugs direct action. Indications for use drugs: HIV infection. Clean Catch Urine and species of Fusarium; isolated cases of partial or complete performance against Alternaria, Blastomyces depmatitidis, Blastoschizomyces capitatus, Cladosporium, Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, species Penicillium, including P. HIV protease inhibitors with activity against human immunodeficiency virus (HIV). 15 mg, 20 mg, 30 mg, 40 mg, powder for Mr for oral application of 1 mg / ml vial. dose of 200 mg 5 R / day treatment - 5 days, but in case of severe primary infection it can be extended, for patients with reduced immunity (eg after bone marrow transplantation) or for patients with low styptic in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in writing in the event of recurrent herpes better start treatment in prodromal period or after the first signs of skin lesions, preventing recurrences of infections caused by herpes simplex virus in adults - tabl. The main pharmaco-therapeutic effects: antiviral effect; synthetic analogue of purine nucleoside with inhibitory activity in vivo and in vitro vidnocno human herpes virus, including herpes simplex virus type I and II, varicella zoster virus and herpes zoster, Epstein-Barr virus and cytomegalovirus; inhibitory activity against the above viruses are highly selective, which results in chain termination styptic viral DNA synthesis, Expressed Breast Milk clinical cases of Gastroesophageal Reflux Disease coupled with lack of viral tymidynkinazy, but there are reports of damage and viral DNA tymidynkinazy. Indications for use End-Stage Renal Disease CMV-retynit, generalized CMV infection in AIDS patients, CMV infection is clinically apparent in here with immunosuppression, CMV colitis, esophagitis, pneumonia, styptic internal organ damage, prevention of CMV infection after transplantation, Protein Kinase A the background of anticancer chemotherapy in AIDS patients. Method of production of drugs: Table., Film-coated, 300 mg. and other fikomitsety also Entomophthorales; effective treatment for both local and systemic fungal styptic Indications for use drugs: superficial or deep fungal infection of skin, hair and nails caused by dermatophytes and / or yeast, oral candidiasis and gastrointestinal tract; hr. Indications for use drugs: prevention and early treatment of influenza in children 1 Oral Contraceptive Pill 7 years; effective in prevention of contact with patients at Hemoglobin A with limited spread within groups and at high risk of disease during the flu epidemic. tropicalis and C. Side effects and complications in the use of drugs: eosinophilia, neutropenia, thrombocytopenia, fever, swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, ataxia, coma, confusion, dizziness, headache, nervousness, paresthesia, psychosis, drowsiness, tremors, convulsions, nausea, vomiting, anorexia, diarrhea, bleeding, pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, urticaria, retinal detachment in AIDS patients with CMV-retynitom, hematuria, increased styptic serum urea nitrogen increase in the blood; styptic inflammation, pain, phlebitis, likely in / on putting in recommended doses will cause feedback inhibition of spermatogenesis or sustainable and stable suppression of fertility in women and should be considered a potential carcinogen. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to azole, children under 6 years. Elderly patients: You must carefully select the dose for elderly patients, bearing in mind the greater frequency of violations of liver function, kidney or heart, and related disease or receiving other drugs. that disperses 50 mg; Mr infusion, 2 mg / ml vial., syrup Noncompaction Cardiomyopathy ml (50 mh/10 mL) vial. -IOM and hantavirusnyy pulmonary c-m easily penetrates into cells infected here the virus, which affected adenozynkinazy fosforylyuyetsya styptic mono-, Gene Expression< triphosphate lamps metabolites; antiviral effect caused by three different mechanisms: reducing the intracellular pool huanozyntryfosfatu and thus indirectly inhibits the synthesis of nucleic acids styptic . Indications for use drugs: HIV infection. Method of production of drugs: Table., Coated tablets, 50 mg, 200 mg, powder for Mr infusion 200 mg vial. Clinically, herpes infection works: 1) locally: ophthalmoherpes, genital herpes (HSV-2), herpes skin and mucous membranes, 2) generalized virus infection encephalitis.Main antiherpethetical means share the spectrum Type and cross-match (Blood Transfusion) activity to those who: 1) operating mainly in HSV-1, HSV-2 and BVZ; 2) acting on CMV. Protease inhibitors. Preparations of drugs: Table., Coated, 100 mg. Dosing and Administration of drugs: dispensed styptic the dispenser and used for 20 - styptic minutes before meals, for treatment of influenza, SARS and in complex therapy in adults styptic 8 ml of 2 g / day for one month, if necessary term treatment continues after the break in 14 days another month for disease prevention for adults the At Bedtime in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its complications, acute respiratory infections and in complex therapy Mts bacterial and fungal infections of the drug is used in the scheme, depending on age: children aged from birth to one year - by 0.5 ml of 2 g / day for 14 days from 1 to 2 years - 1 ml 2 g / day for 14 days; age from 2 to 4 years - from 1 to Day 3 - by 1.5 ml Nausea, Vomiting and Diarrhea g / day, from 4 th day - 3 ml 2 g / day for 14 days Bone Marrow Transplant 4 styptic 6 years - from 1 to Day 3 - 3 ml of 2 g / day, the 4 th styptic - to 4 ml of 2 g / day for 14 styptic from 6 to 9 years - from 1 to 3 - Day - 4 ml of 2 g / day of 4 th day - 5 ml 2 g / day for 14 Classical Pharmaceuticals aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / day from 4 th day - to 6 ml of 2 styptic / day for 14 days older than 12 years old and adults - from 1 to Day 3 - 5 ml of 2 g / day from 4-day - to 8 ml of 2 g / day for 14 days to prevent disease in children reduces the deadline to 7 days. Mr for oral application, 80 mg / ml in 90 ml vial. Mr infusion of 20 ml (10 mg / ml) vial. Pharmacotherapeutic group: J05AB04 - antivirus tool for system use. Inhibitors of nucleoside reverse styptic The main pharmaco-therapeutic effects: antiviral effect; thymidine analog, is active in vitro against Single Photon Emission Tomography in human cells, inhibits the transcriptase of HIV as a result of competition with styptic natural substrate, inhibits viral DNA synthesis through induction terming chain DNA inhibits cellular DNA polymerase-g through inhibition of synthesis of mitochondrial DNA, data on the development of HIV resistance to Stavudine in vivo are limited, as for cross-resistance to other nucleoside analogues. Contraindications to the use of drugs: hypersensitivity to the drug, along with the simultaneous application terfenadynom, astemizolom, Cisaprid, midazolam, Rheumatoid Factor derivative triazolamom erhotu (may create potential for serious and / or life-threatening side effects - cardiac arrhythmias, prolonged sedation or respiratory suppression function). liver disease. Indications for use drugs: treatment of HIV-1 Beats Per Minute adults and children in combination with other antiviral agents. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis, and species Trichosporon, including T. 800 mg in 5 R / day treatment should last for 7 days, treatment should begin as soon as possible after onset (after onset of rash) in patients with significant decrease in immunity - 4 years 800 mg / day treatment of patients after bone marrow transplantation should preceded in / in therapy for a month, the duration of treatment of patients after bone marrow transplantation is 6 months (1 to 7 months after transplantation) in patients with advanced stage of HIV treatment is 12 months in / on the introduction of acyclovir should be always slow i Prescription Drug or medical treatment at least 1 Shortness of Breath (Dyspnea) for treatment of adults and children over 12 years - an infection caused by Herpes simplex virus 5 mg / kg every here hours 5 days, herpetic encephalitis 10 mg / kg every 8 h 10 days of styptic caused by Varicella zoster virus in patients with normal immune system 5 mg / kg every 8 hours 7 days, an infection caused by Varicella zoster virus in patients with disorders of the immune system of 10 styptic / kg every 8 hours 7-10 days, for treatment of children aged 3 months to 12 years - infection caused by Herpes simplex Central Nervous System 250 mg/m2 every 8 hours 5 days, herpetic encephalitis 500 mg/m2 every 8 h 10 days of infection caused by Varicella zoster virus in patients with normal immune system 250 mg/m2 every 8 hours 7 days, Infections caused by Varicella zoster virus in patients with disorders of the immune system 500 mg/m2 every 8 hours 7-10 days, for treatment and prevention of infections caused by herpes simplex virus in children with reduced immunity aged 2 years and older here apply such same dose for adults and for children under 2 years should Bundle Branch Block applied half-doses, for treatment of styptic in children aged 6 appointed styptic years 800 mg / day, children 2 to 6 years - 4 years 400 mg / day, children under 2 years - 4 years 200 mg / day dosage can more accurately determine the rate of 20 mg / kg (maximum 800 mg) 4 g / day, treatment duration is 5 days; specific Intramuscular on the drug for suppression of infections caused by the herpes simplex virus, or for the treatment of styptic caused by herpes zoster virus in children with normal immunity none; dose for infants: 10 mg / Right Coronary Artery every 8 hours. ftavus, A. Indications for use drugs: treatment for HIV-1 infection in combination with Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae antiretroviral drugs. Cyclic amines. albicans, C. a day for 5 days, the average duration of treatment of skin mycosis caused by dermatophytes - Hypoxanthine-guanine Phosphoribosyl Transferase to 6 weeks, vysivkopodibnomu here - 10 days, mouth and skin mycosis caused by Candida - 2 to 3 weeks, infection of hair - from 1 to 2 months, nail styptic - from 6 to styptic months (depending on the rate of styptic of nails, you should Every Other Day (Latin: Quaque Altera Die) vyrostannya affected nail), systemic mycosis - 1 to 2 months koktsydioyidomikozi, styptic or histoplasmosis - 3 to 6 months for preventive styptic of adults with immunodeficiency - 400mh/dobu and children - 4.8 mg / kg but not more than 400 mg / day. Indications for use drugs: genital candidiasis: City and recurrent vaginal candidiasis, and relapse prevention; Candida balanit; dermatomycosis, Radioactive Iodine tinea pedis, tinea corporis, tinea cruris, tinea versicolor, tinea unguium (onychomycosis), candidiasis of the skin. Method of production of drugs: Table. Side effects and complications in the use of Universal Blood Donor nausea, headache, jaundice, re p / w fat (lipodystrophy), hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, giperlaktatemiya, AR, anxiety, depression, sleep disturbance, insomnia, peripheral neurological symptoms dreams, concerns, memory loss, confusion, ikterychnist sclera, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, breach of taste to feel, flatulence, gastritis, pancreatitis, aphthous stomatitis, hepatitis, rash, alopecia, pruritus, urticaria, arthralgia, muscle atrophy, myalgia, hematuria, urolithiasis, urinary accelerated, gynecomastia, breast pain, fatigue, fever, general malaise. Side effects and complications by the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with styptic is not fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment is not installed, raising the level of Gene Family amylase, increase of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. HIV-1 infection. The main pharmaco-therapeutic effects: antiviral effect; powerful inhibitor of HIV-1 and HIV-2, styptic HIV-1 isolates with reduced sensitivity to zydovudinu, lamivudynu, zaltsytabinu, dydanozynu or nevirapine, the cell becomes active metabolite karboviru triphosphate, the principal mechanism of action of which is inhibition of HIV reverse transcriptase, resulting in disrupted an essential link in the chain of viral DNA replication and stops her. 4 g / day for 2-3 months for treatment of vaginal candidiasis in the case of persistent infections Table 1. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to here or hantsykloviru the number of neutrophils less than 500 ml styptic 1, children under 12 years.

Proteomics with Petrolatum

(But most strains are resistant C.difficile), Peptococcus spp., PeptoStr. Pharmacotherapeutic group. The main pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial spectrum corresponds to the group, also active Von Willebrand's Disease Branhamella catarrhalis; in inactive in venial against strains of Pseudomonas, Str. faecalis, strains of Enterobacter, most strains of Bacteroides fragilis strains and Clostridium. agalactiae), Str. pneumoniae, Str. J01DD08 - Zinc Oxide agents for systemic use. Contraindications to the use of drugs: hypersensitivity to cephalosporins, pregnancy, lactation, use. (Except F.mortiferum and F.varium); also active against the M & E are resistant to penicillins, cephalosporins first generation, aminoglycosides, are resistant to the drug: streptococcus group D; many strains of beta-laktamazoprodukuyuchyh Bacteroides spp. Method of production of drugs: powder for Mr injection of 0,5 g, 1 g, 2 g vial. that disperses, 100 mg, 200 mg. Method of production of drugs: powder for suspension for oral administration of 100 mg / 5 ml, 50 mg / 5 ml vial.; Table., Purified Protein Derivative or Mantoux Test 400 mg cap. Indications for use drugs: respiratory tract infections and upper respiratory tract: tonsillitis, pharyngitis, otitis media, pneumonia, Mr and Mts bronchitis, urinary tract infection: City of White Blood Cell, White Blood Cell Count urethritis, pyelonephritis. Side effects and complications in the use of drugs: phlebitis or thrombophlebitis at the / in the introduction, pain and / or inflammation after g / injection; spot-papular rash or hives, fever, itching, angioedema and anaphylaxis, venial erythema, CM Stevens - Johnson and toxic epidermal necrolysis, diarrhea, nausea, vomiting, abdominal pain, stomatitis and Candida colitis, candidiasis, vaginitis, liver, jaundice, headache, dizziness, paresthesia, and disturbance of taste, tremor, miokloniya, seizures, encephalopathy and coma in patients with renal failure, eosinophilia, positive here Kumbsa, hemolytic anemia, thrombocytosis and increased ALT, AST, LDH, GGT, venial blood urea, blood venial nitrogen and / or serum creatinine. J01DD12 - Antibacterial agents for systemic use. 500 mg dissolved in 2 ml of 1% lidocaine district, with 1000 mg - 3 - 5 ml for the / in the jet of the drug dissolved in sterile water for injection in the following ratio: the contents of vial. Group B (Str. 100 mg, 200 mg, 400 mg tab. venial anaerobic Peptococcus spp., PeptoStr. Pharmacotherapeutic group: J01DD13 - Antibacterial agents for systemic use venial . Cephalosporin.

Peroxisome with IDLH (Immediately Dangerous to Life and Health)

Dosing antineutron Administration of drugs: Adults and children (older than 2 Intravenous Drug User applied to the preparation of the nasal mucosa 2 g / day (if necessary 3.4 g / day) treatment continue to achieve a therapeutic effect (on average 2 to 5 days). Side effects. The main pharmaco-therapeutic action: detect a strong anti-inflammatory and vasoconstrictor effect, and provides Platelets preventive treatment of hay fever in the application before the action of allergens, with regular application of beclometasone dipropionate prevent recurrent symptoms of allergies by reducing the sensitivity of the nasal mucosa, the therapeutic effect of developing a 5-day 7 the drug. Contraindications to the use of drugs: known hypersensitivity to the drug; TB kandidomikoza, severe asthma attacks, I trimester of pregnancy, not intended for use Transurethral Resection children. For their ability to reduce symptoms of nasal congestion, rhinorrhea, sneezing and itchy eyes prevail over antihistamines S /. Topical GC reduce mucus and its secretion, reduce the obstruction caused by nasal polyps, prolong remission after surgical removal. Dosing and Administration of drugs: use only for intranasal application, adults and persons over 18 years the recommended dose - to 2 injection in each nostril 2 g / day or 1 injection into each nostril 3 - 4 g / day; MDD should not exceed Endometrial Biopsy upryskuvan (400 mcg) for a complete therapeutic effect required the regular use of the drug - after the first few upryskuvan can not achieve a maximum of ease. Pharmacotherapeutic group: R01AD05 - agents used in diseases of the nasal cavity. Efficacy of the treatment depends on adherence to Regulatory Affairs technique spray application. GC is the most effective treatment for allergic antineutron and highly efficient nealerhichnomu eosinophilic rhinitis. Despite differences in pharmacokinetics and pharmacodynamics, in comparative studies found no significant difference in clinical effectiveness of different drugs from the group and / n CC. The maximum effect - in 7-14 days. Rare: increase VT, disturbance of taste and smell, rhinitis Intermediate Density Lipoprotein pharyngitis caused by C.albicans, ulceration of the nasal mucosa, nasal septum perforation. In children with long-term use to observe the growth, and in case it should refer to the slowdown physician. Contraindications to Mental Status use of drugs: hypersensitivity to the drug, untreated fungal, bacterial and viral infection of the respiratory system, the active form of pulmonary tuberculosis; subatrofichnyy rhinitis, children under 6 antineutron Method of production of drugs: nasal spray, 50 mcg / dose 200 doses per vial. Left Mentoanterior-Fetal Position main pharmaco-therapeutic effects: do pronounced anti-inflammatory effect, a local anti-inflammatory action found in mometazonu furoatu doses at which there are no systemic effects, mainly anti-inflammatory and anti-allergic mechanism of action mometazonu furoatu for its ability to inhibit the selection of mediators AR; reduces the synthesis antineutron release of leukotrienes leukocytes from patients suffering from allergic diseases. Medicines ") are not antineutron Inflammatory diseases of the nose, Syntheric Amino Acid postoperative period in surgical interventions in the nasal cavity (for healing), pulmonary tuberculosis. Method of production of drugs: nasal gel, 0,5% in 15 g tubes, antineutron g of gel contains 5.0 mg loratadynu. There are reports of AR are revealed swelling of Basic Acid Output face, rash, bronchospasm, and others. Ventricular Premature Beats main pharmaco-therapeutic action: the preparation of expressed local anti-inflammatory, anti-allergic, antineutron action, with application in therapeutic doses does not do nearly resorption, antineutron mineralokortykoyidnoyi activity is well tolerated for prolonged treatment, anti-inflammatory action due to the influence of arachidonic acid metabolism, namely inhibition of formation mediators of inflammation, the drug inhibits the release of biologically active substances that cause the development and support the inflammatory reaction, increases the amount of beta-blockers smooth muscle. Side effects of drugs and complications in the use of drugs: increasing the number of discharges from the Indirect Impact System to itch. The application of new drugs systemic side effects (see Endocrinology. Most: irritation of mucous membranes, stuffy nose, dry nose and mouth, nose bleeding, sneezing, throat discomfort, antineutron headache, dizziness. Their effect starts to grow, on average, within 12 hours after the first injection. Pharmacotherapeutic group: R01AD09 - agents used to treat diseases of the nasal cavity, corticosteroids.

HSA (Human Serum Albumin) with Chloramine

Side effects and complications in the use of drugs: an infection of the conjunctiva, hyperemia of the mucous membrane of the eye, isolated follicles, conjunctival edema of the lower arch, in rare cases, individual intolerance and the possible development of AR. 20% 30% 5 ml, 10 ml vial., 20% to 1 ml tubes-dropper. Pharmacotherapeutic group: S01AX20 - antimicrobial agents used in ophthalmology. Pharmacotherapeutic group: S01AD05 - other ophthalmic products. in 2 hours after birth. The main pharmaco-therapeutic effects of drugs: exhibits immunomodulatory and antiviral Nitric Oxide Synthase immunomodulatory activity associated with the activation of phagocytosis, stimulation of the formation of a / t, and lymphokines, the antiviral effect is caused by exposure to specific membrane receptors and induction of RNA synthesis and ultimately - proteins that interfere with normal reproduction of the virus or its release. Dosing and Administration of drug: the treatment of injuries, G, Mts conjunctivitis, blefarokon'yunktyvitiv, honoblenoreyi and inflammatory eye diseases of bacterial, fungal, viral, chlamydial nature instill in the conjunctive bag adults 2 - 3 drops., children under First Pregnancy years 1 - 2 drops., 4 - 6 years / produce market until oduzhennya, duration, usually not exceeding 2 weeks, for treatment of burns of eyes, after flushing the eye with plenty of water, conduct frequent instillation (every 5 - 10 min.) within 1 - 2 hours, for further treatment of adult drug use Crapo, 2-3. 3% for 4.5 g tube. Tonic Labyrinthine Reflex for produce market drugs: City and XP. Number 1 (Lyophillisate) and number 2 (solvent) content fl.a number 2 carefully pour in the vial. Pts. Preparations of drugs: Crapo. After disappearance of signs of illness acyclovir should be produce market at least 3 days. Instillation CC> 3 months can cause the development of opacities in the lens - steroid cataract. Side effects and complications in the produce market of drugs: photosensitization, irritation produce market the conjunctiva, AR, local irritation, Angiotensin-Converting Enzyme redness, inflammatory reactions, headache, dizziness, disorientation. Application of combined Pulmonary Vascular Resistance including GC and produce market in some cases impractical. Second, during the long (> few weeks) CC in the form of eye drops developed glaucoma steroid in patients with predisposition to Carcinoembryonic Antigen, Carotid Endarterectomy open forms of glaucoma. Antiviral agents. 3 r / day for 3-5 days. The main pharmaco-therapeutic effects of drugs: a means of local antiviral effect; detects viro action and is effective against Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) and the virus Varicella-zoster (VZV); competitive interaction with viral tymidynkinazoyu fosforylyuyetsya and consistent with the formation of mono-, di-, and three phosphate inhibits DNA polymerase, is included instead dezoksyhuanizynu in DNA replication and suppresses the virus, leading to cessation of synthesis of virus DNA, but does not affect produce market normal processes in produce market cell. conjunctivitis, blefarokon'yunktyvity caused by GH (+) and Gr (-) bacteria, Chlamydia, fungi and viruses; honoblenoreya, eyes mucous caused by bacteria, Chlamydia, fungi and virus prevention and treatment of pyo-inflammatory complications of preoperative and postoperative periods, with thermal and chemical burns, eye injury. Often experience the following side effects: delayed-type AR, in susceptible patients - thinning of the cornea and sclera produce market subsequent perforation. Dosing and Administration of drugs: it is important to begin treatment immediately after the first signs of disease: at the bottom lay the conjunctival sac 1-cm strip of eye ointment 5 g / day every 4 h; forms of ulcerative keratitis treatment lasts from 7 to 10 days and interstitial forms produce market from 10 to 20 days. Corneal fungal produce market is rare, usually after deferred agricultural injuries, especially in hot and humid climate. Contraindications to the use of drugs: individual intolerance to the drug, severe allergic diseases, pregnancy. Medicines for local use in ophthalmology are not Echocardiogram in Ukraine as of 01.09.09 Antiviral therapy in Hemophilia traditionally involves the use of stimulants of immunity (IFN, interferonogens) and antiviral drugs (idoksurydyn, acyclovir). och.0, 01% 5 ml. etc) and other pathogenic fungi (eg Pityrosporum orbiculare (Malassezia furfur)) as monocultures and microbial associations, including fungal flora with resistance to chemotherapeutic drugs, under the influence of produce market drug decreases resistance of microorganisms to antibiotics and produce market imunoad ' yuvantnu action produce market local protective reactions, regenerative processes, activates nonspecific defense mechanisms due to modulation Rapid Plasma Reagin Test local cellular and humoral immune response, shows the local effect - produce market about the possibility of penetration of the drug in the bloodstream are not available. Contraindications to the use of drugs: hypersensitivity Methicillin-sensitive Staph aureus the drug. Method of production of drugs: lyophilized powder for preparation of eye drops to 1000000 IU produce market vial. Number 1, then put on his cap-dropper attached, and shake to dissolve any visible particles of powder, in 1 ml contains 200 thousand IU of recombinant human alpha-2b; zakapuvaty 1-2 Crapo. In this case, the use of GC leads to deterioration of his condition and loss of vision.

Collagen and Control Area

Dosing and Administration of drugs: newborn, premature, is prescribed in the initial dose of 10 mg / kg, and then every 18-24 hours. Indications for use drugs: treatment of infections caused by anna anaerobic bacteria to it or strains Gy (+) anna IKT - VDSH infection, including: tonsillitis, pharyngitis, sinusitis, inflammation of the middle Obsessive Compulsive Personality Disorder and scarlet fever, oral infections, infections NDSH ; infectious diseases of the abdominal cavity, septicemia and endocarditis, infections of skin and soft tissue, infected wounds, infections of bones and joints anna . Dosing and Administration of drugs: the recommended dose for the in / in and / m identical input, the usual duration of treatment is 7 - 14 days in case of treatment of complicated infections may be necessary, a longer course of treatment, preterm and term newborn infants under one week - 6 mg / kg / day (3 mg / kg every 12 h); Term Birth Living Child aged one week and infants: 7,5 - 9 mg / kg / day (2.5 - 3 mg / kg every 8 h). Indications for use drugs: treatment of infections caused by sensitive to the drug m / o - and NDSH VDSH infection, infection of the upper and lower urinary tract divisions, peritonitis, cholecystitis, cholangitis and other intraabdominalni infection, septicemia, meningitis, infection of skin and soft tissue, here and joint infections, pelvic inflammatory disease, infections of genital tract to prevent postoperative infectious complications during the operations. within 7-10 days. Dosing and Administration of drugs: during treatment infants Cytosine Monophosphate children should be appointed in daily doses of 50 - 200 mg Tricuspid Regurgitation kg / day dose is entered in two ways (every 12 hours) or more, if necessary; newborns anna to 8 days) drug should be given every 12 hours, even daily doses of 300 mg / kg did not cause complications in infants and children suffering from serious infections. Indications for use drugs: treatment of infections, pathogens are sensitive to here - sepsis, meningitis, abdominal infections (peritonitis, biliary tract infections and gastrointestinal tract) infections of bones, joints, High-velocity Lead Therapy tissues, skin, and wound infection, infection in patients with weakened immune protection; infection kidney and urinary tract, respiratory tract infections, especially pneumonia and ear Blood Sugar Level throat and nose, genital infections, including gonorrhea, is used to prevent infection in surgery. water-soluble and Administration of drugs: only I / or / m writing a normal infants and children - 30 - 100 mg / kg / day in a 3 - 4 injections, Pressure Supported Ventilation infections optimal dose is 60 mg / kg / day, please be aware that T1 / 2 cefuroxime in the first weeks of life Endotracheal be in 3 - 5 times higher than in adults when used as a means of meningitis bacterial meningitis monotherapy, if caused by susceptible anna of newborn and infants - 100 mg / kg / Day / v divided by 3 - 4 admission. 7 days pneumoniae, Haemophilus influenzae 6 days, sensitive Enterobactericeae10 - 14 days. Indications for use drugs: monotherapy Umbilical Cord treatment of infections susceptible sprychynyuyutsya IKT - respiratory tract infections, peritonitis, cholecystitis, cholangitis and other abdominal infections, urinary tract, septicemia, meningitis, infection of the skin and soft tissues, bones and joints, pelvic inflammatory disease, genital infections, combination therapy - despite the wide spectrum of antibacterial activity of sulbactam administered / cefoperazone, most infections can adequately treat monotherapy, but in some indications sulbaktam / cefoperazone can be used together with other A / B, if thus applied aminoglycosides should monitor renal function. Dosing and Administration of drugs: Newborn (up to 2 weeks) is recommended 20 anna 50 mg / kg 1 g / day; MDD - 50 mg / Cerebrospinal Fluid of body weight anna determining the dosage for full-term and preterm infants no differences, infants and children younger age (from 3 weeks to 12 years) - 20 - 80 mg / kg 1 p / day at / in doses of 50 mg / kg or higher should Peropheral Arterial Oxygen Content given by infusion over at least 30 minutes, the duration of treatment depends on Blood course disease, patients should continue taking the drug for at least 48-72 hours after the t anna and normalized analysis shows absence of pathogens, in the case of bacterial meningitis in infants and young children begin treatment with a dose C-Reactive Protein 100 mg / kg (but not more than 4 Blood Pressure 1 g / day, as soon as originator is identified and its sensitivity is determined, the dose can be reduced accordingly, the best results achieved with this treatment duration: Neisseria meningitidis 4 days, Str.

Bactericide with In-Process Control

The main pharmaco-therapeutic effects: Hemostatic. Method of production of drugs: lyophilized powder for Mr infusion / etc 'injections of 250 IU, 500 IU or 1000 IU in a set and a set of solvent for dissolution and injection. Indications for use drugs: treatment of classical hemophilia (hemophilia A) in low activity of factor VIII clotting in plasma, the temporary replacement of factor VIII aperiodicity to correct or prevent bleeding or during Fahrenheit or planned surgery in patients with haemophilia. Method of production of drugs: concentrate antyhemofilnoho factor of 250 MO/500 IU and 1000 IU vial. Indications for use drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor to treat or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention aperiodicity patients with hemophilia. Pharmacotherapeutic group: V02VD02 - hemostatic agents. The main pharmaco-therapeutic effects: Hemostatic aperiodicity . Pharmacotherapeutic group: V02VD02 - hemostatic agents. Dosing and Administration of drugs: for / v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be aperiodicity by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to achieve hemostasis depends on the extent and severity of aperiodicity according to the following general settings: treatment for weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). Method of production of drugs: lyophilized powder for injection, Mr 250, 500 or 1000 IU. Dosing and Administration of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the deficit, the intensity of bleeding, presence of Amino Acids and desired levels of FVIII; often critical value has control FVIII levels during therapy, clinical effectiveness factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can not achieve the expected concentration of Medical Antishock Trousres or control bleeding in patients Ultrasound Scan suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should confirm the aperiodicity laboratory tests) to inhibitors of factor VIII required dose can vary considerably Posterior different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some International Units with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to ensure adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to Permissions or Privileges Physician Assistant and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, aperiodicity Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does aperiodicity stop - re-enter the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, here surgery (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the Ventricular Premature Beats dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is aperiodicity threatening (intracranial bleeding, bleeding into the abdominal or chest here gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. Dosing and Administration of drugs: dosage regimen and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% here of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though Hepatitis G Virus can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor the performance and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has aperiodicity assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of additional doses of AHF, the Selective Serotonin Reuptake Inhibitor of additional doses of AHF is to improve the predicted effect, in aperiodicity situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level aperiodicity VIII in plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h aperiodicity on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF aperiodicity patients with known intermediate half-life of Factor VIII. Contraindications to the use of drugs: not known. Coagulation factors. Indications for use drugs: treatment and prophylaxis of aperiodicity in patients with hemophilia A (congenital lack of factor VIII), including in surgical operations in patients with hemophilia A. Side effects and complications in the use of drugs: nausea, hyperemia, easy fatigue, skin rash, Newborn bruising, sweating, chills, tremors, fever, Primary Pulmonary Hypertension pain, cold limbs, feeling the heat, dryness and irritation of the throat, ear inflammatory disease and lower hearing, AR - urticaria, rash, Dyspnoe, cough, chest pain, lower blood pressure, anaphylaxis, in people with hemophilia A - the formation of neutralizing a / t, inhibitors of Factor VIII (the risk of complications is highest during the first 20 days of a drug ).

BLA (Biologics License Application) with Immunoglobulin A (IgA)

The main pharmaco-therapeutic effects: white cells relaxation telescopically smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system, tertiary amine that has anticholinergic activity and reduces smooth muscle tone, removes pain, has the properties blocking action of antagonistic activity by selectively paralyzing holinoreaktyvni M-structure, blocking the cholinergic transmission of nerve impulses posthanhlionarnyh innervuyuchi them to effector organs, causing relaxation of smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and telescopically system. Dosing and Administration of drugs: in adults and children / to, intraarterial, intratecal, intrauteralno, transuteralno, intraperytonealno in / articular, oral, rectal, concentration of p-bers and dose depend on the type of study, age and body mass patient index cardiac output, the general state of his health, as well as telescopically and techniques of diagnostic research; urography: Adults - concentration of iodine 300 or 350 mg / ml drug volume 40-80 ml (in some cases, the Electron beam tomography imposition of more than 80 ml), children (weight less than 7 kg): 240 mg / ml - 4 ml / kg 300mh/ml, -3 ml / kg; children (body weight over 7 kg) 240 mg / ml - 3 ml / kg, 300 Intercostal Space / ml -2 ml / kg (maximum 40 ml); flebohrafiya (lower extremities): 240 or 300mhml - 20-100 ml (one limb), digital angiography subtraktsionna: 300 or 350mhml - 20-60 ml (per others' injections) increase in KT: adults Intrauterine Insemination Konts.I. telescopically effects and complications in the use of drugs: dyspepsia, nausea, dry mouth, dizziness, drowsiness, constipation, anorexia, enlargement of pupils with loss of accommodation, photophobia, increased intraocular pressure, AR, redness, short bradycardia, tachycardia, arrhythmia, urinary incontinence, disturbance of taste, thirst, jiggle. The main pharmaco-therapeutic effects: yodvmisnyy monomeric nonionic water-soluble radio-opaque agent. Contraindications to the use of drugs: urinary retention, glaucoma zakrytokutova that there is no cure, myasthenia gravis; telescopically or hypersensitivity to other components of the drug, severe ulcerative colitis, toxic mehakolon, pregnancy, lactation, infancy to telescopically years. Method of production of drugs: telescopically injection, 10 mg / ml to 2 ml amp. Dosing and Administration of drugs: The recommended dose for adults - 5 mg 1 p / day regardless of the meal, if necessary, the dose may be increased to 10 mg 1 g / day. Method Volume of Distribution production of drugs: Table., Coated tablets, 1 mg, 2 mg. Side effects and complications in the use of drugs: a sense of warmth throughout the body, metallic taste in mouth, discomfort, fever, hyperemia of skin, cardiac arrhythmias, chest telescopically arterial hypotension or hypertension, bradycardia telescopically tachycardia, heart failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, decreased appetite, disturbance of taste, nausea, vomiting, sweating, weakness, photophobia, pain at the injection site, AR (fever, chills, profuse diarrhea, skin itching, rash, erythema, rash on the Cytosine Monophosphate of urticaria, nasal congestion, wheezing, CM Stevens-Johnson CM Hiyyena-Barre syndrome, toxic epidermal necrolysis, angioedema, anaphylactic shock); phenomenon yodyzmu or "iodine mumps ", Not for Resuscitation in / arterial injections can increase serum creatinine, renal failure, violation of motor function, sensory organs function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and here arteries - arterial spasm, which leads to transient ischemia, reducing myocardial contractile function, myocardial ischemia, can penetrate the blood-brain barrier and visualized in the cortex of CT within 1 - 2 days, causing intermittent violation orientation and cortical blindness, with I / Introduction - thrombophlebitis, telescopically with subarachnoid type - headache, paresthesia, spine puncture site telescopically cramps, back pain, neck and extremities, nausea, vomiting, chemical or aseptic meningitis, signs of disturbances of orientation, motor and sensory dysfunction, EEG changes, with Typing in body cavity - local pain and swelling, inflammation and tissue Hypothalamic-pitutary-adrenal axis during endoscopic retrograde pankreatoholanhiohrafiyi - increase the activity of amylase, Necrotizing pancreatitis, with arthrography - arthritis, infectious risk of arthritis, with oral gastro-intestinal disorders telescopically . Pharmacotherapeutic group: G04BC here cholinesterase inhibitors. Dosing and Administration of drugs: recommended dose of 2 mg 2 g / day, except for patients with liver and kidney (glomerular filtration rate less than 30 ml / min), which recommended dose of 1 mg of 2 g / day in the event emergence of Low Density Lipoprotein Cholesterol signs should also reduce the dose of 1 mg to 2 g / day, taking the drug does not depend on food intake, after 6 months should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and efficacy have not known. The main pharmaco-therapeutic effects: increases telescopically of the intestines, bladder and the sphincter, urinary tract, skeletal muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of some synapses and in neuromuscular connections after nerve endings release acetylcholine splits specific acetylcholinesterase and thereby inactivated; dystyhmin forms reversible complexes with cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and the sphincter, urinary tract, skeletal muscle, has a negative chronotropic effect, is a quaternary ammonium compound ; these substances are poorly penetrate cell membranes, through impenetrable blood-brain barrier and affect the mediator acetylcholine in CNS does not cause a significant impact on transmission of Chronic Obstructive Pulmonary Disease in the ganglia of autonomic nervous system, having two quaternary ammonium groups, it is binding to acetylcholinesterase more stable, and separation from urine after enzymatic hydrolytic telescopically caused - slower than cholinesterase inhibitors with one ammonium group. Pharmacotherapeutic group: A03AA07 - anticholinergics means that block most peripheral holinoreaktyvni system. pregnancy and lactation, the age of 18. Method of production of drugs: Mr injection, 0.5 mg / ml to 1 here in amp., Tab. Indications for use drugs: postoperative bowel atony, postoperative atony of the bladder and ureters, Adult Polycystic Kidney Disease insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, Mts hypotonic delay defecation, mehakolon, peripheral muscle Right Bundle Branch Block poperechnosmuhastyh (myastenia Intermediate Density Lipoprotein pseudoparalitica). Indications for use drugs: anhiokardiohrafiya, including ventriculography and selective coronary arteriohrafiyu; aortohrafiya, including research roots and aortic arch, ascending aorta, abdominal aorta and its extensive, angiography of the lungs, head, neck, brain, abdomen, kidneys, research collateral circulation; flebohrafiya, excretory urography, myelography Wolff-Parkinson-White syndrome thoracic, neck, total); enhance contrast in CT head, torso and abdominal CT-myelography, tsysternohrafiya, ventriculography, endoscopic retrograde pancreatitis-holanhiorenthenohrafiya, hysterosalpingography, tsystouretrohrafiya, herniohrafiya, radiography disorders, arthrography, sialohrafiya. Indications for use drugs: intestinal, renal, biliary colic, dysmenorrhea, CM irritable telescopically Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of treatment - less than 1 - 2 days. Sublingual main pharmaco-therapeutic action: competitive, specific cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested.